top of page
The Professional Network for Healthcare Experts
FDA approves Labcorp PGDx elio tissue complete CDx for BRAF-targeted therapy selection in advanced melanoma
The next-generation sequencing companion diagnostic identifies BRAF V600E and V600K variants, helping clinicians determine which melanoma patients may be eligible for FDA-approved BRAF or BRAF/MEK targeted therapies.
nuaxia
5 days ago2 min read
FDA grants accelerated approval to Tudriqev for PD-1-refractory advanced melanoma
The engineered oncolytic viral therapy, used with nivolumab, provides a new treatment option for adults with unresectable cutaneous melanoma that has progressed despite prior PD-1-based immunotherapy.
nuaxia
Aug 72 min read
bottom of page